Friday October 20, 2017 06:57

Heathcare Press Release : 15 Jun 2017

LEO Pharma Starts Phase 3 Clinical Study for Tralokinumab in Atopic Heathcare—15 Jun 17

LEO Pharma today announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that specifically targets the cytokine IL-13[1], which plays an important role in

Merck Awarded its First CRISPR Patent by Australian Patent Office Heathcare—15 Jun 17

- Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR - Similar patents pending in other countries; anticipate favorable outcomes , a leading science and technology company, today